Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma
Brief Summary: This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.


Options:
A: Arm Label: PARTICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: PARTICS using QVAR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PARTICS using QVAR; Assigned to Arm(s): PARTICS
B: Arm Label: BDA MDI (PT027) 160/180 μg; Type: EXPERIMENTAL; Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg | Arm Label: BDA MDI (PT027) 80/180 μg; Type: EXPERIMENTAL; Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg | Arm Label: AS MDI (PT007) 180 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol sulfate metered-dose inhaler 180 μg | Intervention Type: COMBINATION_PRODUCT; Name: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg; Assigned to Arm(s): BDA MDI (PT027) 160/180 μg | Intervention Type: COMBINATION_PRODUCT; Name: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg; Assigned to Arm(s): BDA MDI (PT027) 80/180 μg | Intervention Type: DRUG; Name: Albuterol sulfate metered-dose inhaler 180 μg; Assigned to Arm(s): AS MDI (PT007) 180 µg
C: Arm Label: steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: prednisolone | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): placebo, steroid
D: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6

Answer: B